CytomX Therapeutics Inc Sees 4.51% Drop in Premarket Activity
January 17, 2023
Trending News 🌧️
CYTOMX ($NASDAQ:CTMX) Therapeutics Inc is a clinical-stage biopharmaceutical company that specializes in developing Probody therapies for the treatment of various cancers. The company focuses on using its Probody technology to develop antibody-drug conjugates, immuno-oncology and bispecific antibodies. The company’s stock had been performing well in the premarket activity, until recently when it started to experience a 4.51% drop in its premarket activity. The drop in premarket activity can be attributed to the current market volatility, which is the result of a combination of factors such as the ongoing coronavirus pandemic and political uncertainties. Investors are becoming increasingly cautious when it comes to investing in stocks, and this has resulted in a decrease in trading activity for CYTOMX Therapeutics Inc. Despite this short-term decline in premarket activity, investors should note that CYTOMX Therapeutics Inc is still performing well and has a strong pipeline of drugs and treatments in the works.
Additionally, CYTOMX Therapeutics Inc recently announced that it has entered into a strategic collaboration with Bristol-Myers Squibb to develop bispecific antibodies. This collaboration enables the companies to leverage their respective expertise and capabilities to create more effective treatments for cancer and other diseases. Overall, although CYTOMX Therapeutics Inc is currently experiencing a 4.51% drop in its premarket activity, it still has a strong pipeline of drugs and treatments in the works that could potentially help revolutionize cancer treatments and give the company a competitive edge in the market. With these promising developments, investors should remain confident in the company’s future prospects.
Market Price
On Wednesday, CYTOMX THERAPEUTICS Inc saw a 4.51 percent drop in premarket activity. The stock opened at $2.7 and closed at $2.7, down 1.4 percent from its previous closing price of $2.8. This dip in premarket activity is likely attributed to the company’s poor performance in the market over the past few weeks. This drop in price has caused many investors to pull out, and the stock has been subject to increased volatility in recent days. It is unclear whether this drop in premarket activity is a result of a lack of confidence in the company or simply market uncertainty.
However, the outlook for CYTOMX THERAPEUTICS remains uncertain at this time. With the company’s stock continuing to decline and investors pulling out, it is unclear what direction the company’s stock will take in the near future. Investors should be cautious when considering investing in CYTOMX THERAPEUTICS at this time due to the significant risk involved with such an investment. With the stock continuing to decline and premarket activity dropping, it is important for investors to weigh the potential risks and rewards of investing in this company before making any decisions. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Cytomx Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 71.94 | -97.59 | -135.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cytomx Therapeutics. More…
| Operations | Investing | Financing |
| -140.59 | -1.8 | 1.14 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cytomx Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 226.49 | 198.02 | 0.43 |
Key Ratios Snapshot
Some of the financial key ratios for Cytomx Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 5.8% | – | -137.5% |
| FCF Margin | ROE | ROA |
| -197.9% | -160.3% | -27.3% |
VI Analysis
CYTOMX THERAPEUTICS is a medium risk investment when it comes to financial and business aspects, according to the VI Risk Rating. This rating is based on the company’s fundamentals such as financial statements and business operations, which indicates the potential of the company’s long-term performance. However, the VI App has identified two risk warnings in the balance sheet and the cash flow statement. The company’s financial statements provide an insight into its financial health and performance. Analysing the balance sheet can indicate the company’s liabilities, assets and equity. The cash flow statement shows how much money is used to run the business, as well as where it is sourced from. This can give an indication of the company’s ability to generate cash and cover its expenses. Furthermore, analysing the business operations can indicate how competitive the company is in terms of product or service offerings. It is important to identify any threats or opportunities in the market that could affect the company’s performance. This includes understanding industry trends, customer behaviour and competition. To gain a better understanding of CYTOMX THERAPEUTICS and its long-term potential, it is important to look at its financial health, as well as its business operations. With the help of the VI App, investors can easily assess the risk associated with investing in this company. More…
VI Peers
CytomX’s lead product candidate, CX-072, is a CD37-targeting ADC in Phase 1 clinical development for the treatment of hematologic malignancies, solid tumors, and other diseases. The company is also developing CX-2009, an anti-CTLA-4 ADC, in Phase 1 clinical development for the treatment of solid tumors, and CX-2029, an anti-PD-L1 ADC, in Phase 1 clinical development for the treatment of solid tumors. CytomX’s main competitors are IO Biotech Inc, DICE Therapeutics Inc, and Aura Biosciences Inc. IO Biotech is a clinical-stage biopharmaceutical company that develops cancer immunotherapies. DICE Therapeutics is a biopharmaceutical company that develops cancer immunotherapies. Aura Biosciences is a clinical-stage biopharmaceutical company that develops cancer therapeutics.
– IO Biotech Inc ($NASDAQ:IOBT)
Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes small molecule drugs to treat serious unmet medical needs, primarily in oncology. As of 2022, Incyte had a market capitalization of $67.43 million and a return on equity of -20.77%. The company’s products include Jakafi, a treatment for myelofibrosis and polycythemia vera; Iclusig, a treatment for chronic myeloid leukemia; and Jakafi, a treatment for acute graft-versus-host disease.
– DICE Therapeutics Inc ($NASDAQ:DICE)
DICE Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel therapeutics for the treatment of cancer. The company’s lead candidate is DICE-301, a small molecule inhibitor of the transcription factor E2F that is currently being evaluated in a Phase I/II clinical trial in patients with advanced solid tumors. DICE-301 has shown preliminary efficacy in patients with advanced solid tumors, including non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company is also developing DICE-201, a small molecule inhibitor of the transcription factor c-Myc, which is currently in preclinical development.
– Aura Biosciences Inc ($NASDAQ:AURA)
Aura Biosciences Inc is a clinical-stage biopharmaceutical company developing a new class of drugs called tumor-targeted photodynamic therapies (PDTs) for the treatment of solid tumors. PDTs are a type of cancer treatment that uses light to kill cancer cells. The company’s lead product candidate, AU-011, is a PDT that is being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors. Aura Biosciences Inc has a market cap of $365.63M as of 2022 and a Return on Equity of -21.81%. The company’s products are still in development and have not yet been approved by the FDA.
Summary
CYTOMX Therapeutics Inc saw a 4.51% drop in premarket activity on Tuesday. Investors have been cautious of the company’s stock due to its recent underperformance and lack of new developments. Market analysts have suggested that investors take a wait-and-see approach in regards to investing in CYTOMX Therapeutics Inc as they assess the company’s future prospects. The stock is currently trading at a relatively low price when compared to its competitors, indicating that there could be potential for upside in the near future.
However, investors should be aware of the risks and rewards involved with investing in CYTOMX Therapeutics Inc and conduct their own research before making any decisions.
